Does valproic acid warrant therapeutic drug monitoring in bipolar affective disorder?

Therapeutic Drug Monitoring

Volumn 32, Issue 1, 2010, Pages 19-29

  Haymond, Jennifer ^a   Ensom, Mary H H ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b CHILDREN S AND WOMEN S HEALTH CENTRE OF BRITISH COLUMBIA   (Canada)

Author keywords

Bipolar affective disorder; Mania; Pharmacokinetics; Therapeutic drug monitoring; Valproic acid

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CHLORPROMAZINE; CIMETIDINE; ERYTHROMYCIN; FELBAMATE; FLUOXETINE; LITHIUM; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; TOPIRAMATE; VALPROATE SEMISODIUM; VALPROIC ACID;

ABDOMINAL CRAMP; ACUTE DISEASE; ACUTE HEMORRHAGIC PANCREATITIS; AGRANULOCYTOSIS; ALGORITHM; AMINOTRANSFERASE BLOOD LEVEL; ATAXIA; BEHAVIOR DISORDER; BIOAVAILABILITY; BIPOLAR DISORDER; BIPOLAR MANIA; CIRCADIAN RHYTHM; CLINICAL TRIAL; CONTROLLED STUDY; DECISION MAKING; DIARRHEA; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG METABOLISM; DRUG MONITORING; DRUG POTENTIATION; DRUG RELEASE; DRUG RESPONSE; DRUG SAFETY; EPILEPSY; FLATULENCE; GASTROINTESTINAL TOXICITY; HAND TREMOR; HEPATITIS; HUMAN; HYPERAMMONEMIA; HYPERANDROGENISM; INDIGESTION; LETHARGY; LEUKOPENIA; MANIA; MEDICAL LITERATURE; MENSTRUAL IRREGULARITY; MOOD DISORDER; NAUSEA; NONHUMAN; OVARY POLYCYSTIC DISEASE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PRURITUS; REVIEW; SEDATION; SEIZURE; SIDE EFFECT; SINGLE DRUG DOSE; THROMBOCYTOPENIA; TREATMENT DURATION; TREMOR; VOMITING; WEIGHT GAIN;

ALGORITHMS; ANIMALS; ANTIMANIC AGENTS; BIPOLAR DISORDER; DRUG MONITORING; HUMANS; VALPROIC ACID;

EID: 75649115718     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3181c13a30     Document Type: Review

References (63)

1. Wilbur K, Ensom MHH. Pharmacokinetic drug interactions between oral contraceptives and second-generation anticonvulsants. Clin Pharmacokinet. 2000;38:355-365.
2. MacRitchie K, Geddes JR, Scott J, et al.Valproate for acute mood episodes in bipolar disorder. Cochrane Database Syst Rev. 2003;1:CD004052. doi: 10.1002/14651858.
3. Bowden CL. Spectrum of effectiveness of valproate in neuropsychiatry. Expert Rev Neurother. 2007;7:9-16.
4. Fankhauser MP. Bipolar disorder. In: Dipiro J, ed. Pharmacotherapy: A Pathophysiological Approach. 5th ed. Toronto, Canada: McGraw-Hill; 2002:1265-1287.
5. Hirschfeld RM, Bowden CL, Gitlin MJ, et al. Practice Guideline for the Treatment of Patients With Bipolar Disorder. 2nd ed. American Psychiatric Assocation Web site. April, 2002. Available at: http:// www.psychiatryonline. com/pracGuide/pracGuideTopic-8.aspx. Accessed March 16, 2008.
6. Baldessarini RJ. Drugs and the treatment of psychatric disorders: depression and mania. In: Hardman JG, Limbird LE, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 9th ed. New York: MacGraw-Hill; 1996:431-459.
7. Crismon ML, Argo TR, Bendele SD, et al.Texas medication algorithm project procedural manual: bipolar disorder algorithms. The Texas Department of State Health Services Web site. August 15, 2008. Available at: http://www.dshs.state. tx.us/mhprograms/disclaimer.shtm. Accessed November 8, 2008.
8. Yatham LN, Kennedy SH, O'Donovan C, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies. Bipolar Disord. 2005;7(Suppl 3):5-69.
9. Fleming J, Chetty M. Therapeutic monitoring of valproate in psychiatry: how far have we progressed? Clin Neuropharmacol. 2006;29:350-360.
10. Azorin JM, Findling RL. Valproate use in children and adolescents with bipolar disorder. CNS Drugs. 2007;21:1019-1033.
11. Ensom MHH, Davis GA, Cropp CD, et al. Clinical pharmacokinetics in the 21st century: does the evidence support definitive outcomes? Clin Pharmacokinet. 1998;34:265-279.
12. Vasudev K, Das S, Goswami U, et al. Pharmacokinetics of valproic acid in patients with bipolar disorder. J Psychopharmacol. 2001;15:187-190.
13. Gerner RH, Stanton A. Algorithm for patient management of acute manic states: lithium, valproate, or carbamazepine? J Clin Psychopharmacol. 1992;12(Suppl 1):57S-63S.
14. Alldredge BK. Anticonvulsants. In: Anderson PO, ed. Handbook of Clinical Drug Data. 10th ed. Toronto: McGraw-Hill; 2002:415-442
15. Epival product monograph. In: Repchinsky C, ed. Compendium of Pharmaceuticals and Specialties. Ottawa, Canada: Canadian Pharmacists Association; 2008.
16. Yatham LN, Kennedy SH, O'Donovan C, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007. Bipolar Disord. 2006;8:721-739.
17. MacRitchie KA, Geddes JR, Scott J, et al.Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder. Cochrane Database Syst Rev. 2001;3:CD003196. doi: 10.1002/14651858.
18. Bowden CL, Calabrese JR, McElroy SL, et al. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Arch Gen Psychiatry. 2000;57:481-489.
19. Morriss RK, Faizal MA, Jones AP, et al. Interventions for helping people recognize early signs of recurrence in bipolar disorder (review). Cochrane Database Syst Rev. 2007;1:CD004854. doi: 10.1002/14651858.
20. Krogh M, Johansen K, Tønnesen F, et al. Solid-phase microextraction for the determination of the free concentration of valproic acid in human plasma by capillary gas chromatography. J Chromatogr B. 1995;637: 299-305.
21. Amini H, Javan M, Ahmadiani A. Development and validation of a sensitive assay of valproic acid in human plasma by high-performance liquid chromatography without prior derivatization. J Chromatogr B. 2006;830:368-371.
22. Elyas AA, Goldberg VD, Ratnaraj N, et al. Valproic acid estimation by enzyme immunoassay. Ann Clin Biochem. 1980;17:307-310.
23. Nakajima M, Yamato S, Shimada K, et al. Assessment of drug concentrations in tears in therapeutic drug monitoring: I. Determination of valproic acid in tears by gas chromatography/mass spectrometry with EC/NCI mode. Ther Drug Monit. 2000;22:716-722.
24. Monaco F, Piredda S, Mutani R, et al. The free fraction of valproic acid in tears, saliva, and cerebrospinal fluid. Epilepsia. 1982;23:23-26.
25. Davis R, Peters DH, McTavish D. Vaplproic acid: a reappraisal of its pharmacological properties and clinical efficacy in epilepsy. Drugs. 1994: 47:332-372.
26. Johannessen S. Therapeutic drug monitoring of antiepileptic drugs. In: Hempel G, ed. Handbook of Analytical Separations. New York: Elsevier; 2004:221-253.
27. College of American Pathologists. Surveys 2009 Therapeutic Drug Monitoring (General) Participant Summary. Northfield, IL: College of American Pathologists 2009, 37-40.
28. Vasudev K, Goswami U, Kohli K. Carbamazepine and valproate monotherapy: feasibility, relative safety and efficacy, and therapeutic drug monitoring in manic disorder. Psychopharmacology. 2000;150: 15-23.
29. Perry PJ, Bever-Stille KA, Arndt S, et al. Correlation of valproate plasma concentrations and dose in bipolar affective disorder [letter]. J Clin Psychopharmacol. 2000;20:277-279.
30. Bowden CL, Janicak PG, Orsulak P, et al. Relation of serum valproate concentration to response in mania. Am J Psychiatry. 1996;153:765-770.
31. Martel J, Despres N, Dillon PW, et al. Evaluation of the valproic acid assay on the Bayer Technicon Immuno 1 System. Clin Biochem. 1997;30:372.
32. Braun SL, Tausch A, Vogt W, et al. Evaluation of a new valproic acid enzyme immunoassay and comparison with a capillary gas-chromato-graphic method. Clin Chem. 1981;27:169-172.
33. Leroux M, Budnik D, Hall K, et al. Comparison of gas-liquid chromatography and emit assay for serum valproic acid. Clin Biochem. 1981;14:87-90.
34. Product information. TDx/TDxFLx Valproic Acid Assay. Abbott Park, IL: Abbott Laboratories Diagnostics Division; 2007.
35. Beckman Coulter Inc. Valproic Acid (VPA) assay. Bulletin 9282 TDM 12. Available at: http://www.beckmancoulter.com/literature/ClinDiag/ 9282%20tdm12%20VPA%201002.pdf Accessed February 14, 2009.
36. Snodgrass SR, Parks BR. Anticonvulsant blood levels: historical review with a pediatric focus. J Child Neurol. 2000;15:734-746.
37. Gidal BE, Garnett WR, Graves N. Epilepsy. In: Dipiro J, ed. Pharmacotherapy: A Pathophysiological Approach. 5th ed. Toronto, Canada: McGraw-Hill; 2002:1031-1059.
38. McNamara JO. Drugs effective in the therapy of the epilepsies. In: Hardman JG, Limbird LE, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 9th ed. New York: MacGraw-Hill; 1996: 461-486.
39. Brodie MJ, Dichter MA. Antiepileptic drugs. N Engl J Med. 1996;334: 168-175.
40. Tomson T, Dahl ML, Kimland E.Therapeutic monitoring of antiepileptic drugs for epilepsy. Cochrane Database Syst Rev. 2007;2:CD002216. doi: 10.1002/14651858.
41. Jannuzzi G, Cian P, Fattore C, et al. A multicenter randomized controlled trial on the clinical impact of therapeutic drug monitoring in patients with newly diagnosed epilepsy. Epilepsia. 2000;41:222-230.
42. Young RC, Biggs JT, Ziegler VE, et al. A rating scale for mania: reliability, validity, and sensitivity. Br J Psychiatry. 1978;133:429-435.
43. Mullen J, Endicott J, Hirschfeld RM, et al, eds. Manual of Rating Scales for the Assessment of Mood Disorders. Wilmington, DE: AstraZeneca Parmaceuticals LP; 2004: 14.
44. Poolsup N, Li Wan Po A, Oyebode F. Measuring mania and critical appraisal of rating scales. J Clin Pharm Ther. 1999;24:433-443.
45. Pope HG, McElroy SL, Keck PE, et al. Valproate in the treatment of acute mania: a placebo-controlled study. Arch Gen Psychiatry. 1991;48: 62-68.
46. McElroy SL, Keck PE, Pope HG, et al. Correlates of antimanic response to valproate. Psychopharmacol Bull. 1991;27:127-133.
47. Bowden CL, Brugger AM, Swann AC, et al. Efficacy of divalproex vs lithium and placebo in the treatment of mania. JAMA. 1994;271:918-924.
48. Hirschfeld RA, Allen MH, McEvoy JP, et al. Safety and tolerability of oral loading divalproex sodium in acutely manic bipolar patients. J Clin Psychiatry. 1999;60:815-818.
49. Keck PE, Bowden CL, Meinhold JM, et al. Relationship between serum valproate and lithium levels and efficacy and tolerability in bipolar maintenance therapy. Int J Psychiatry Clin Pract. 2005;9:271-277.
50. Tohen M, Baker RW, Altshuler LL, et al. Olanzapine versus divalproex in the treatment of acute mania. Am J Psychiatry. 2002;159:1011-1017.
51. Allen MH, Hirschfeld RM, Wozniak PJ, et al. Linear relationship of valproate serum concentration to response and optimal serum levels for acute mania. Am J Psychiatry. 2006;163:272-275.
52. Grahnen A, Karlsson MO. Concentration-controlled or effect-controlled trials. Clin Pharmacokinet. 2001;40:317-325.
53. Haidukewych D, John G, Zielinski JJ, et al. Chronic valproic acid therapy and incidence of increases in venous plasma ammonia. Ther Drug Monit. 1985;7:290-294.
54. Ratnaike RN, Schapel GJ, Purdie G, et al. Hyperammonaemia and hepatotoxicity during chronic valproate therapy: enhancement by combination with other antiepileptic drugs. Br J Clin Pharmacol. 1986;22:100-103.
55. Kugoh T, Yamamoto M, Hosokawa K. Blood ammonia level during valproic acid therapy. Jpn J Psychiatry Neurol. 1986;40:663-668.
56. Dealberto M-JCC. Valproate-induced hyperammonaemic encephalopa-thy: review of 14 cases in the psychiatric setting. Int Clin Psychophar-macol. 2007;22:330-337.
57. American Society of Health-System Pharmacists. Valproate sodium, valproic acid, divalproex sodium. In: AHFS Drug Information 2008. Available at: http://online.statref.com. Accessed November 8, 2008.
58. Ohdo S, Nakano S, Ogawa N. Circadian changes of valproate kinetics depending on meal condition in humans. J Clin Pharmacol. 1992;32: 822-826.
59. Gidal BE, Pitterle ME, Spencer NW, et al. Relationship between valproic acid dosage, plasma concentration and clearance in adult monotherapy patients with epilepsy. J Clin Pharm Ther. 1995;20:215-219.
60. Wilkinson GR. Clearance approaches in pharmacology. Pharmacol Rev. 1987:39:1-47.
61. Bauer LA, Davis R, Wilensky A, et al. Valproic acid clearance: unbound fraction and diurnal variation in young and elderly adults. Clin Pharmacol Ther. 1985;37:697-700.
62. El Desoky E, Kandil MR, Afifi A-HM, et al. Spotlight on the continual applicability of routine plasma monitoring antiepileptic drugs in the treatment of epilepsy. Pharmacol Res. 1999;39:269-274.
63. Scott J, Pope M. Self-reported adherence to treatment with mood stabilizers, plasma levels, and psychiatric hospitalization. Am J Psychiatry. 2002;159:1927-1929.